These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29017279)

  • 1. Population-Level Herd Protection of Males From a Female Human Papillomavirus Vaccination Program: Evidence from Australian Serosurveillance.
    Pillsbury AJ; Quinn HE; Evans TD; McIntyre PB; Brotherton JML
    Clin Infect Dis; 2017 Sep; 65(5):827-832. PubMed ID: 29017279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Liu B; Bateson D; McNamee K; Garefalakis M; Phillips S; Cummins E; Malloy M; Garland SM
    Lancet Infect Dis; 2014 Oct; 14(10):958-66. PubMed ID: 25107680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herd immunity effect of the HPV vaccination program in Australia under different assumptions regarding natural immunity against re-infection.
    Korostil IA; Peters GW; Law MG; Regan DG
    Vaccine; 2013 Apr; 31(15):1931-6. PubMed ID: 23434388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
    Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
    PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human Papillomavirus (HPV) Vaccine Effectiveness and Potential Herd Immunity for Reducing Oncogenic Oropharyngeal HPV-16 Prevalence in the United Kingdom: A Cross-sectional Study.
    Mehanna H; Bryant TS; Babrah J; Louie K; Bryant JL; Spruce RJ; Batis N; Olaleye O; Jones J; Struijk L; Molijn A; Vorsters A; Rosillon D; Taylor S; D'Souza G
    Clin Infect Dis; 2019 Sep; 69(8):1296-1302. PubMed ID: 30590469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009-2013.
    Cameron RL; Kavanagh K; Pan J; Love J; Cuschieri K; Robertson C; Ahmed S; Palmer T; Pollock KG
    Emerg Infect Dis; 2016 Jan; 22(1):56-64. PubMed ID: 26692336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final analysis of a study assessing genital human papillomavirus genoprevalence in young Australian women, following eight years of a national vaccination program.
    Garland SM; Cornall AM; Brotherton JML; Wark JD; Malloy MJ; Tabrizi SN;
    Vaccine; 2018 May; 36(23):3221-3230. PubMed ID: 29724506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geographical disparities in human papillomavirus herd protection.
    Berenson AB; Hirth JM; Chang M
    Cancer Med; 2020 Jul; 9(14):5272-5280. PubMed ID: 32483924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postlicensure monitoring of HPV vaccination programmes.
    Markowitz LE; Hariri S
    Lancet Infect Dis; 2014 Oct; 14(10):904-5. PubMed ID: 25107681
    [No Abstract]   [Full Text] [Related]  

  • 11. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
    Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials.
    Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M
    Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fall in human papillomavirus prevalence following a national vaccination program.
    Tabrizi SN; Brotherton JM; Kaldor JM; Skinner SR; Cummins E; Liu B; Bateson D; McNamee K; Garefalakis M; Garland SM
    J Infect Dis; 2012 Dec; 206(11):1645-51. PubMed ID: 23087430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of Self-reported Human Papillomavirus Vaccination Status Among Gay and Bisexual Adolescent Males: Cross-sectional Study.
    Chow EP; Fairley CK; Wigan R; Hocking JS; Garland SM; Cornall AM; Tabrizi SN; Chen MY
    JMIR Public Health Surveill; 2021 Dec; 7(12):e32407. PubMed ID: 34874884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of human papillomavirus in teenage heterosexual males following the implementation of female and male school-based vaccination in Australia: 2014-2017.
    Chow EPF; Tabrizi SN; Fairley CK; Wigan R; Machalek DA; Regan DG; Hocking JS; Garland SM; Cornall AM; Atchison S; Bradshaw CS; McNulty A; Owen L; Marshall L; Russell DB; Kaldor JM; Chen MY
    Vaccine; 2019 Oct; 37(46):6907-6914. PubMed ID: 31562001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
    Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R
    Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus prevalence and risk factors among Australian women 9-12 years after vaccine program introduction.
    Shilling H; Garland SM; Atchison S; Cornall AM; Brotherton JML; Bateson D; McNamee K; Kaldor JM; Hocking JS; Chen MY; Fairley CK; McNulty A; Bell C; Marshall L; Ooi C; Skinner SR; Murray G; Molano M; Tabrizi S; Machalek DA
    Vaccine; 2021 Aug; 39(34):4856-4863. PubMed ID: 34281743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High seroprevalence of multiple high-risk human papillomavirus types among the general population of Bonaire, St. Eustatius and Saba, Caribbean Netherlands.
    Vos RA; Pasmans H; Tymchenko L; Janga-Jansen AVA; Baboe-Kalpoe S; Hulshof K; de Melker HE; van der Klis FRM
    Vaccine; 2020 Mar; 38(13):2816-2826. PubMed ID: 32088019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination.
    Machalek DA; Garland SM; Brotherton JML; Bateson D; McNamee K; Stewart M; Rachel Skinner S; Liu B; Cornall AM; Kaldor JM; Tabrizi SN
    J Infect Dis; 2018 Apr; 217(10):1590-1600. PubMed ID: 29425358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of human papillomavirus type replacement among young pregnant Finnish females before and after a community-randomised HPV vaccination trial with moderate coverage.
    Gray P; Kann H; Pimenoff VN; Adhikari I; Eriksson T; Surcel HM; Vänskä S; Dillner J; Faust H; Lehtinen M
    Int J Cancer; 2020 Dec; 147(12):3511-3522. PubMed ID: 32574384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.